A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma (Q38730197)

5 September 2017

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma (English)

1 reference

5 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Rossella Elisei

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Cristina Romei

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

12 February 2016

1 reference

Nature Reviews Endocrinology

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

192-202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrendo.2016.11

12 June 2020

exact match

0 references

cites work

Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Is there really an increased incidence of thyroid cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Advances in the follow-up of differentiated or medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Multiple endocrine neoplasia type 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Activation of a novel human transforming gene, ret, by DNA rearrangement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET tyrosine kinase signaling in development and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Structure and physiology of the RET receptor tyrosine kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Alternative splicing results in RET isoforms with distinct trafficking properties.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

The GDNF family ligands and receptors - implications for neural development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

GFRalpha3 is an orphan member of the GDNF/neurturin/persephin receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Minireview: RET: normal and abnormal functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

The clinical spectrum of RET proto-oncogene mutations in codon 790.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Defining "mutation" and "polymorphism" in the era of personal genomics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Early Malignant Progression of Hereditary Medullary Thyroid Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RAS proto-oncogene in medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpoints in papillary thyroid carcinomas of children after Chernobyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Frequency of close positioning of chromosomal loci detected by FRET correlates with their participation in carcinogenic rearrangements in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Cancer consequences of the Chernobyl accident: 20 years on.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Risk of thyroid cancer after exposure to 131I in childhood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET/PTC rearrangement in thyroid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

ret/PTC-1 Activation in Hashimoto Thyroiditis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET/PTC Rearrangement--a link between Hashimoto's thyroiditis and thyroid cancer...or not

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET fusion as a novel driver of medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET/PTC rearrangement occurring in primary peritoneal carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

KIF5B-RET fusions in lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Medullary thyroid cancer: management guidelines of the American Thyroid Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Fine-needle aspiration of the thyroid: today and tomorrow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Oncogene profile of papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Targeted therapies for thyroid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Approach to the patient with advanced differentiated thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Cabozantinib in progressive medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.11

A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8)

31 March 2020

1 reference

12 December 2020

Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.

1 reference

12 December 2020

Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

1 reference

12 December 2020

[MEN IIB. A case report]

1 reference

12 December 2020

Integrated genomic characterization of papillary thyroid carcinoma

1 reference

12 December 2020

Molecular pathology of differentiated thyroid cancer.

1 reference

12 December 2020

Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET

1 reference

12 December 2020

Characterization of the ret proto-oncogene products expressed in mouse L cells

1 reference

12 December 2020

Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method

1 reference

12 December 2020

Radiation-induced thyroid tumors

1 reference

12 December 2020

RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes

1 reference

12 December 2020

The physical map of the human RET proto-oncogene.

1 reference

12 December 2020

The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults

1 reference

12 December 2020

RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults

1 reference

12 December 2020

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

1 reference

12 December 2020

Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications

1 reference

12 December 2020

Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.

1 reference

12 December 2020

A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene

1 reference

12 December 2020

Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer.

1 reference

12 December 2020

High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant

1 reference

12 December 2020

ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?

1 reference

12 December 2020

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma

1 reference

12 December 2020

Differentiated thyroid cancer in children and adults: same or distinct disease?

1 reference

12 December 2020

BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.

1 reference

12 December 2020

Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma

1 reference

12 December 2020

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

1 reference

12 December 2020

Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice

1 reference

12 December 2020

Oncogene profile of papillary thyroid carcinoma.

1 reference

12 December 2020

Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients

1 reference

12 December 2020

The ret/PTC oncogene in papillary thyroid carcinoma

1 reference

12 December 2020

Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2016.11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868437%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference